JP2023542539A5 - - Google Patents

Info

Publication number
JP2023542539A5
JP2023542539A5 JP2023518849A JP2023518849A JP2023542539A5 JP 2023542539 A5 JP2023542539 A5 JP 2023542539A5 JP 2023518849 A JP2023518849 A JP 2023518849A JP 2023518849 A JP2023518849 A JP 2023518849A JP 2023542539 A5 JP2023542539 A5 JP 2023542539A5
Authority
JP
Japan
Prior art keywords
cells
human
mouse
tumor
human immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051734 external-priority patent/WO2022066894A1/en
Publication of JP2023542539A publication Critical patent/JP2023542539A/ja
Publication of JP2023542539A5 publication Critical patent/JP2023542539A5/ja
Pending legal-status Critical Current

Links

JP2023518849A 2020-09-24 2021-09-23 免疫細胞療法を評価するためのヒト化マウスモデル Pending JP2023542539A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063083016P 2020-09-24 2020-09-24
US202063083003P 2020-09-24 2020-09-24
US63/083,003 2020-09-24
US63/083,016 2020-09-24
PCT/US2021/051734 WO2022066894A1 (en) 2020-09-24 2021-09-23 Humanized mouse models for assessing immune cell therapy

Publications (2)

Publication Number Publication Date
JP2023542539A JP2023542539A (ja) 2023-10-10
JP2023542539A5 true JP2023542539A5 (cg-RX-API-DMAC7.html) 2024-07-30

Family

ID=80845843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518849A Pending JP2023542539A (ja) 2020-09-24 2021-09-23 免疫細胞療法を評価するためのヒト化マウスモデル

Country Status (8)

Country Link
US (2) US12196744B2 (cg-RX-API-DMAC7.html)
EP (1) EP4216971A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023542539A (cg-RX-API-DMAC7.html)
KR (1) KR20230074758A (cg-RX-API-DMAC7.html)
AU (1) AU2021347320A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196823A1 (cg-RX-API-DMAC7.html)
IL (1) IL301634A (cg-RX-API-DMAC7.html)
WO (1) WO2022066894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11959925B2 (en) 2017-04-17 2024-04-16 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug for use in humans
WO2023060126A1 (en) * 2021-10-06 2023-04-13 Dana-Farber Cancer Institute, Inc. Engineered cytokine receptors for tunable adoptive cell therapy
WO2024029561A1 (ja) * 2022-08-02 2024-02-08 学校法人東海大学 担がん-免疫不全非ヒト動物、これを用いた供試物質に関するがん免疫応答評価方法
CN117686676B (zh) * 2023-12-15 2025-05-30 扬州大学 一种基于多水平生物标志物响应法评价水中污染物转代生物效应的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
US7105158B1 (en) 1992-11-16 2006-09-12 The Corporation Of Mercer University Methods of administering microencapsulated materials for immune modulated diseases
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2006007529A2 (en) 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Immunosuppressive exosomes
JP2007244268A (ja) 2006-03-15 2007-09-27 Osaka Prefecture Univ イヌの造血前駆細胞を認識するモノクローナル抗体の製造方法
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
CN101715485A (zh) 2007-04-06 2010-05-26 国际干细胞公司 源于人单性生殖胚泡的患者特异性干细胞系
WO2011036308A1 (en) 2009-09-28 2011-03-31 Theramab Gmbh Method for preclinical testing of immunomodulatory drugs
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
CN102971420B (zh) 2010-04-14 2016-10-26 哈伦实验室有限公司 无毛nod scid小鼠
EP2422618A1 (en) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
WO2013086019A1 (en) 2011-12-06 2013-06-13 Massachusetts Institute Of Technology Use of humanized mice to determine toxicity
CN103304669A (zh) 2012-03-12 2013-09-18 复旦大学 人源化肿瘤免疫细胞因子tntil2及其制备方法和用途
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
DK4389764T3 (da) 2012-11-05 2026-04-13 Regeneron Pharma Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf
EP2976641B1 (en) 2013-03-22 2018-01-03 Imperial Innovations Ltd In vitro method for assessing cytokine storm responses
TWI810145B (zh) * 2015-06-23 2023-08-01 杰克森實驗室 具有病患衍生之異種移植物之非hla配對的人源化nsg小鼠模式
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
CN110099998A (zh) * 2016-10-26 2019-08-06 艾欧凡斯生物治疗公司 冷冻保存的肿瘤浸润淋巴细胞的再刺激
WO2018102546A1 (en) 2016-11-30 2018-06-07 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
US11959925B2 (en) 2017-04-17 2024-04-16 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug for use in humans
US11778994B2 (en) * 2017-05-12 2023-10-10 The Jackson Laboratory NSG mice lacking MHC class I and class II
US20190091310A1 (en) * 2017-09-26 2019-03-28 Stephen E. Wright Nonreleased il-12 for therapy of cancer
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
WO2019084018A1 (en) * 2017-10-23 2019-05-02 City Of Hope CAR FOR THE TREATMENT OF HIV INFECTION
CN110055223A (zh) * 2018-01-19 2019-07-26 北京百奥赛图基因生物技术有限公司 一种B2m基因改造的免疫缺陷动物的制备方法及其应用
US20210214723A1 (en) * 2018-06-01 2021-07-15 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
WO2020206149A2 (en) * 2019-04-05 2020-10-08 The Regents Of The University Of California Methods and compositions involving chimeric binding polypeptides

Similar Documents

Publication Publication Date Title
Zhong et al. Cytokines and chemokines in HBV infection
Dorner et al. Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection
Barnes et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model.
Skinnider et al. The role of interleukin 13 in classical Hodgkin lymphoma
Hillinger et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model
Smith et al. Production of interleukin-10 by human bronchogenic carcinoma
Curtsinger et al. Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function
Yoo et al. IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways
Kitaya et al. Spatial and temporal expression of ligands for CXCR3 and CXCR4 in human endometrium
Fisman et al. Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof
Sharma et al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma
Lingnau et al. IL-4 in combination with TGF-β favors an alternative pathway of Th1 development independent of IL-12
Wang et al. Cytokines frequently implicated in myeloproliferative neoplasms
Punnonen et al. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors
Zhang et al. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis
JP2019536457A5 (cg-RX-API-DMAC7.html)
Sotnikova et al. Cytokine network of eutopic and ectopic endometrium in women with adenomyosis
Schmidt et al. IL-17 receptor C signaling controls CD4+ TH17 immune responses and tissue injury in immune-mediated kidney diseases
Rosati et al. Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations
Trümper et al. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease
Nath et al. Macrophage inflammatory protein (MIP) 1 α and MIP1 β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy
Mikita et al. Recent advances in cytokines in cutaneous and systemic lupus erythematosus
Hou et al. Rapid downregulation of programmed death‐1 and interferon‐γ‐inducible protein‐10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B
Kennedy et al. Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis
Zhao et al. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer